CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS M.E.Z. Capra, M. Beksac, P.G. Richardson, A. Unal, P. Corradini, S. Delimpasi, Z. Gulbas, G. Mikala, A. Neylon, A. Symeonidis, S. Bringhen, P. Moreau, H.V. Velde, F. Campana, S.L. Guennec, I. Spicka